DE

563.11

+1.22%↑

FDX

356.21

+4.24%↑

HEICO

273.76

+3.63%↑

HEICA

211

+3.31%↑

CPRT

33.2

+1.68%↑

DE

563.11

+1.22%↑

FDX

356.21

+4.24%↑

HEICO

273.76

+3.63%↑

HEICA

211

+3.31%↑

CPRT

33.2

+1.68%↑

DE

563.11

+1.22%↑

FDX

356.21

+4.24%↑

HEICO

273.76

+3.63%↑

HEICA

211

+3.31%↑

CPRT

33.2

+1.68%↑

DE

563.11

+1.22%↑

FDX

356.21

+4.24%↑

HEICO

273.76

+3.63%↑

HEICA

211

+3.31%↑

CPRT

33.2

+1.68%↑

DE

563.11

+1.22%↑

FDX

356.21

+4.24%↑

HEICO

273.76

+3.63%↑

HEICA

211

+3.31%↑

CPRT

33.2

+1.68%↑

Search

Apogee Enterprises Inc

Geschlossen

BrancheIndustrie

33.52 3.33

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

32.18

Max

33.52

Schlüsselkennzahlen

By Trading Economics

Einkommen

-7.1M

17M

Verkäufe

-9.6M

349M

KGV

Branchendurchschnitt

17.348

51.05

Dividendenrendite

3.2

Gewinnspanne

4.748

Angestellte

4,500

EBITDA

-3.8M

41M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+38.72% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

3.20%

2.30%

Nächstes Ergebnis

23. Apr. 2026

Nächste Dividendenausschüttung

27. Mai 2026

Nächstes Ex-Dividendendatum

12. Mai 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-102M

698M

Vorheriger Eröffnungskurs

30.19

Vorheriger Schlusskurs

33.52

Nachrichtenstimmung

By Acuity

21%

79%

47 / 405 Ranking in Industrials

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

Apogee Enterprises Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

31. März 2026, 23:31 UTC

Heiße Aktien

Stocks to Watch: Nike, RH, NCino

31. März 2026, 22:35 UTC

Ergebnisse

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1. Apr. 2026, 00:00 UTC

Akquisitionen, Fusionen, Übernahmen

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31. März 2026, 23:50 UTC

Akquisitionen, Fusionen, Übernahmen

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31. März 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31. März 2026, 23:33 UTC

Market Talk
Wichtige Nachrichtenereignisse

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31. März 2026, 23:21 UTC

Ergebnisse

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31. März 2026, 23:14 UTC

Market Talk
Ergebnisse

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31. März 2026, 23:12 UTC

Market Talk

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31. März 2026, 22:36 UTC

Ergebnisse

China Vanke 2025 Loss Widens >000002.SZ

31. März 2026, 22:36 UTC

Ergebnisse

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31. März 2026, 22:36 UTC

Ergebnisse

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31. März 2026, 22:36 UTC

Ergebnisse

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31. März 2026, 22:36 UTC

Ergebnisse

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31. März 2026, 21:46 UTC

Akquisitionen, Fusionen, Übernahmen

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31. März 2026, 21:36 UTC

Market Talk

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31. März 2026, 21:35 UTC

Ergebnisse

Nike Expects China Sales Down 20% in 4Q, CFO Says

31. März 2026, 21:35 UTC

Ergebnisse

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31. März 2026, 21:35 UTC

Ergebnisse

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31. März 2026, 21:33 UTC

Akquisitionen, Fusionen, Übernahmen

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31. März 2026, 21:33 UTC

Ergebnisse

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31. März 2026, 21:32 UTC

Ergebnisse

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31. März 2026, 21:28 UTC

Ergebnisse

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31. März 2026, 21:26 UTC

Ergebnisse

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31. März 2026, 21:25 UTC

Ergebnisse

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31. März 2026, 21:24 UTC

Market Talk
Ergebnisse

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31. März 2026, 21:22 UTC

Ergebnisse

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31. März 2026, 21:22 UTC

Ergebnisse

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31. März 2026, 21:21 UTC

Ergebnisse

Nike's Digital Channel Still Too Promotional, CFO Says

31. März 2026, 21:20 UTC

Ergebnisse

Nike CEO: Converse Remains Important to Portfolio

Peer-Vergleich

Kursveränderung

Apogee Enterprises Inc Prognose

Kursziel

By TipRanks

38.72% Vorteil

12-Monats-Prognose

Durchschnitt 45 USD  38.72%

Hoch 46 USD

Tief 44 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Apogee Enterprises Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

2

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

40.03 / 40.44Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

Weak Bearish Evidence

Langfristig

Strong Bearish Evidence

Stimmung

By Acuity

47 / 405 Ranking in Industrie

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Apogee Enterprises Inc

Apogee Enterprises, Inc. provides architectural products and services for enclosing buildings, and glass and acrylic products used for preservation, protection, and enhanced viewing in the United States, Canada, and Brazil. The company operates in four segments: Architectural Framing Systems, Architectural Glass, Architectural Services, and Large-Scale Optical (LSO). The Architectural Framing Systems segment designs, engineers, fabricates, finishes, and installs custom glass and aluminum window, curtainwall, storefront, and entrance systems for the exterior of buildings primarily in the non-residential construction sectors. The Architectural Glass segment provides a range of high-performance glass products for use in windows, curtainwall, storefront, and entrance systems. The Architectural Services segment integrates technical services, project management, and field installation services to design, engineer, fabricate, and install building glass and curtainwall systems. The LSO segment manufactures high-performance glazing products for the custom framing, fine art, and engineered optics markets. The company's products and services are primarily used in commercial buildings, such as office buildings, hotels, and retail centers; institutional buildings comprising education facilities, health care facilities, and government buildings; transportation facilities, such as airports and transit terminals, as well as multi-family residential buildings. It markets its architectural products and services through direct sales force, independent sales representatives, distributors, and glazing subcontractors and general contractors; and value-added glass and acrylics through retail chains, as well as independent distributors to museums, galleries, and other customers. The company was incorporated in 1949 and is based in Minneapolis, Minnesota.
help-icon Live chat